Interest in mistletoe for cancer has grown in North America, ever since Suzanne Somers announced on Larry King Live that she is using it to treat her breast cancer. European mistletoe has been used for treating cancer since the 1920s, especially in Europe. Several brand name mistletoe extracts are available there: Iscador, Eurixor, Helixor, Isorel, Vysorel, and ABNOBAviscum. So far these products are not readily available in North America. There is no proof that they work for breast or other cancers. Using European mistletoe can also be unsafe. Avoid these products and stick with proven cancer treatments.
How does it work ?
Uses & Effectiveness ?
Possibly Ineffective for
- Head and neck cancer. Injecting European mistletoe extract into the skin before or after surgery or radiation for head and neck cancers does not improve survival.
Insufficient Evidence for
- Bladder cancer. Some early research suggests that administering European mistletoe extract into the bladder for 6 weeks might reduce bladder cancer recurrence in people who have had bladder cancer surgery. Injecting European mistletoe into the skin for several months might slow the progression of bladder cancer.
- Breast cancer. Some early research suggests that injecting certain brands of European mistletoe extract into the skin might reduce tumor growth and improve survival in people with breast cancer. But these results have been questioned. Also, a higher quality study did not find benefit. So far, there isn't enough reliable evidence to support using European mistletoe for this type of cancer. Stick to proven treatments.
- Colon cancer, rectal cancer. Early research suggests that certain specific European mistletoe extracts, given by injection alone or with conventional therapy, might improve survival in people with colon cancer. But these results have been questioned. So far, there isn't enough reliable evidence to support using European mistletoe for this type of cancer. Stick to proven treatments.
- Common cold. Early research suggests that a specific European mistletoe extract, given by injection for 12 weeks, might not treat or prevent the common cold.
- Stomach cancer. Early research suggests that a specific European mistletoe extract, given by injection under the skin, might improve survival in people with stomach cancer. It might also increase immune function. Benefits of European mistletoe have been questioned. So far, there isn't enough reliable evidence to support using European mistletoe for this type of cancer. Stick to proven treatments.
- Swelling (inflammation) of the liver caused by the hepatitis C virus (hepatitis C). Research about the effectiveness of European mistletoe in people with hepatitis C is conflicting. Some research suggests that injecting a specific extract of European mistletoe may help to fight the infection that causes hepatitis C and improve quality of life in some people. Other research shows that injecting a different European mistletoe product does not help fight the hepatitis C infection but may improve symptoms of hepatitis C.
- Cancer of the white blood cells (leukemia). Early research suggests that injecting a specific European mistletoe extract might increase the survival of people with chronic myeloid leukemia by more than 2 years.
- Lung cancer. There is some limited contradictory evidence about the effectiveness of European mistletoe on survival in people with lung cancer. So far, there isn't enough reliable evidence to support using European mistletoe for this type of cancer. Stick to proven treatments.
- Build up of fluid and cancer cells in the space between the chest wall and lung (malignant pleural effusions). Early research suggests that giving a specific European mistletoe extract into the pleural space decreases cancer in those with cancer of that area.
- The most serious type of skin cancer (melanoma). Early research suggests that injecting a specific European mistletoe extract into the skin does not improve survival or increase the time period without the disease in people with melanoma.
- Ovarian cancer. Early research suggests injecting a specific European mistletoe extract into the skin might help patients with ovarian cancer and undergoing other treatments live longer.
- Pancreatic cancer. Injecting European mistletoe extract into the skin does not seem to increase remission rates in people with advanced pancreatic cancer. But it might improve survival by about 2 months in people with pancreatic cancer who are no longer able to receive chemotherapy treatment. European mistletoe extract might also help improve survival time when injected into the tumor in people with pancreatic cancer who are receiving chemotherapy.
- Quality of life. Early research suggests that injecting various European mistletoe extracts into the skin might improve quality of life and well-being in people with cancer when given alone or with chemotherapy.
- Radiation exposure. Early research suggests that injecting a specific type of European mistletoe extract into the skin for 5 weeks might reduce lung infections and improve symptoms, such as fatigue, sweating, headache, joint pain, emotional instability, and muscle pain in children with repeated lung infections caused by radiation exposure during the Chernobyl nuclear accident.
- Cancer of the uterus. Early research suggests that injecting a specific type of European mistletoe extract into the skin may to improve survival in people with cancer of the uterus.
- High cholesterol.
- Internal bleeding.
- Menstrual disorders.
- Side effects of chemotherapy and radiation therapy.
- Sleep disorders.
- Other conditions.
When given as a shot: European mistletoe is POSSIBLY SAFE when injected beneath the skin in appropriate amounts. However, larger amounts are LIKELY UNSAFE and can cause serious side effects. Injecting European mistletoe beneath the skin or into the vein can cause fever, chills, skin rashes, pain, nausea, vomiting, allergic reactions, and other side effects.
Because the correct amount is sometimes hard to determine, do not take European mistletoe without the advice of your healthcare professional.
Special Precautions and Warnings
There isn't enough reliable information about the safety of taking European mistletoe if you are breast-feeding. Stay on the safe side and avoid use.
"Auto-immune diseases" such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: European mistletoe might cause the immune system to become more active, and this could increase the symptoms of auto-immune diseases. If you have one of these conditions, it's best to avoid using European mistletoe.
Heart disease: There is some evidence European mistletoe might make heart disease worse. Don't use it if you have a heart problem.
Leukemia: Some test tube studies suggested European mistletoe might be effective against childhood leukemia. But benefits have not been shown in people. In fact, European mistletoe might make leukemia worse. If you have leukemia, don't take European mistletoe.
Liver disease: There is some concern that taking European mistletoe might harm the liver. In theory, European mistletoe might make liver diseases, such as hepatitis, worse. People with liver disease or a history of liver disease should avoid European mistletoe.
Organ transplant: European mistletoe might make the immune system more active. This would be a problem for people who have received an organ transplant. A more active immune system might increase the risk of organ rejection. If you have had an organ transplant, avoid European mistletoe.
Surgery: European mistletoe might affect blood pressure. There is a concern that it might interfere with blood pressure control during and after surgery. Stop taking European mistletoe at least 2 weeks before a scheduled surgery.
Medications for high blood pressure (Antihypertensive drugs) interacts with EUROPEAN MISTLETOE
European mistletoe seems to decrease blood pressure. Taking European mistletoe along with medications for high blood pressure might cause your blood pressure to go too low.
Some medications for high blood pressure include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.
Medications that decrease the immune system (Immunosuppressants) interacts with EUROPEAN MISTLETOE
European mistletoe seems to increase the immune system. By increasing the immune system European mistletoe might decrease the effectiveness of medications that decrease the immune system.
Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
Be cautious with this combination
Bauer C, Oppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol 2005;94:86-9. View abstract.
Böcher E, Stumpf C, Büssing A, and et al. [Prospective assessment of toxicity of high dose Viscum album L. infusions in patients with progressive malignomas]. Zeitschrift fur Onkologie 1996;28(4):97-106.
Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med. 2012;2012:219402. View abstract.
Bussing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995;94:199-205.. View abstract.
Bussing A, Stumpf C, Troger W, Schietzel M. Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts. Anticancer Res. 2007 Jul-Aug;27(4C):2903-10. View abstract.
Cazacu, M., Oniu, T., Lungoci, C., Mihailov, A., Cipak, A., Klinger, R., Weiss, T., and Zarkovic, N. The influence of isorel on the advanced colorectal cancer. Cancer Biother.Radiopharm. 2003;18(1):27-34. View abstract.
Chernyshov VP, Omelchenko LI, Heusser P, and et al. Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complementary Therapies in Medicine 1997;5(3):141-146.
Chernyshov, V. P., Heusser, P., Omelchenko, L. I., Chernyshova, L. I., Vodyanik, M. A., Vykhovanets, E. V., Galazyuk, L. V., Pochinok, T. V., Gaiday, N. V., Gumenyuk, M. E., Zelinsky, G. M., Schaefermeyer, H., and Schaefermeyer, G. Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident. Am J Ther. 2000;7(3):195-203. View abstract.
Cho SJ, Kim SW, Chang JW. Acute pneumonitis consequent on pleurodesis with Viscum album extract: severe chest images but benign clinical course. Multidiscip Respir Med. 2014 Nov 27;9(1):61. View abstract.
Deliorman D, Calis I, Ergun F. A new acyclic monoterpene glucoside from Viscum album ssp. album. Fitoterapia 2001;72:101-5.
Dold U, Edler L, Maurer HC, et al., eds. [Adjuvant Cancer Therapy in Advanced Non-Small Cell Bronchial Cancer: Multicentric Controlled Studies To Test the Efficacy of Iscador and Polyerga]. Stuttgart, Germany: Georg Thieme Verlag, 1991.
Douwes FR, Kalden M, Frank G, and et al. [Treatment of advanced colorectal carcinoma: efficacy test of the combination of 5-fluorouracil and tetrahydrofolic acid versus 5-fluorouracil and tetrahydrofolic acid in combination with an optimized Helixor treatment]. Deutsche Zeitschrift für Onkologie 1988;3:63-67.
Douwes, F. R., Wolfrum, D. I., and Migeod, F. [Results of a prospective randomized study on chemotherapy versus chemotherapy plus "biological response modifier" in metastatic colorectal carcinoma]. Krebsgeschehen 1986;18(6):155-164.
Elsasser-Beile U, Leiber C, Wolf P, et al. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 2005;174:76-9. View abstract.
Enesel, M. B., Acalovschi, I., Grosu, V., Sbarcea, A., Rusu, C., Dobre, A., Weiss, T., and Zarkovic, N. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 2005;25(6C):4583-4590. View abstract.
Ernst E, Schmidt K, Steuer-Vogt MK. Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 2003;107:262-7.. View abstract.
Evans M, Bryant S, Huntley AL, Feder G. Cancer Patients' Experiences of Using Mistletoe (Viscum album): A Qualitative Systematic Review and Synthesis. J Altern Complement Med. 2016 Feb;22(2):134-44. View abstract.
Finall AI, McIntosh SA, Thompson WD. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ 2006;333:1293-4. View abstract.
Friess H, Beger HG, Kunz J, et al. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996 Mar-Apr;16:915-20. View abstract.
Gorter, R. W., van Wely, M., Reif, M., and Stoss, M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern.Ther.Health Med 1999;5(6):37-38. View abstract.
Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementarmed 2006;13:285-92. View abstract.
Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung. 2007;57(10):665-78. View abstract.
Grossarth-Maticek, R. and Ziegler, R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 11-30-2006;11(11):485-495. View abstract.
Grossarth-Maticek, R. and Ziegler, R. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur.J Med Res 3-31-2008;13(3):107-120. View abstract.
Grossarth-Matichek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 2001;7:57-66, 68-72, 74-6 passim. View abstract.
Gutsch J, Berger H, Scholz G, and et al. [Prospective study of different adjuvant therapies (polychemotherapy, Helixor or control) of patients treated with radical mastectomy for breast cancer]. Deutsche Zeitschrift für Onkologie 1988;21:94-101.
Gutsch J. [On the state of therapy of chronic myeloid leukemia in adults with the mistletoe preparation Helixor]. Ärztezeitschrift für Naturheilverfahren Physikalische Medizin Und Rehabilitation 1982;23(9):523-544.
Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed) 1981;282:186-7. View abstract.
Heiny BM. [Adjuvant treatment with standardized mistletoe extract reduces leukopenia and improves the quality of life of patients with advanced carcinoma of the breast getting palliative chemotherapy (VEC regimen)]. Krebsmedizin 1991;12:3-14.
Heinzerling L, von Baehr V, Liebenthal C, et al. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol 2006;26:347-59. View abstract.
Huber R, Barth H, Schmitt-Graff A, Klein R. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med 2000;6:305-10. View abstract.
Huber R, Klein R, Lüdtke R, Werner M. [Frequency of the common cold in healthy subjects during exposure to a lectin-rich and a lectin-poor mistletoe preparation in a randomized, double-blind, placebo-controlled study]. Forsch Komplementarmed Klass Naturheilkd. 2001 Dec;8(6):354-8. View abstract.
Huber R, Schlodder D, Effertz C, Rieger S, Troger W. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med. 2017 Sep 18;17(1):465. View abstract.
Huber, R., Ludtke, R., Klassen, M., Muller-Buscher, G., Wolff-Vorbeck, G., and Scheer, R. Effects of a mistletoe preparation with defined lectin content on chronic hepatitis C: an individually controlled cohort study. Eur.J Med Res 9-28-2001;6(9):399-405. View abstract.
Jung ML, Baudino S, Ribereau-Gayon G, et al. Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 1990;51:103-8.. View abstract.
Kaegi E. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998;158:1157-9. View abstract.
Khan T, Ali S, Qayyum R, Hussain I, Wahid F, Shah AJ. Intestinal and vascular smooth muscle relaxant effect of Viscum album explains its medicinal use in hyperactive gut disorders and hypertension. BMC Complement Altern Med. 2016 Jul 27;16:251. View abstract.
Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters. BMC Complement Altern Med. 2011 Aug 28;11:72. View abstract.
Kim HJ, Kim H, Ahn JH, Suk JH. Liver injury induced by herbal extracts containing mistletoe and kudzu. J Altern Complement Med 2015;21(3):180-5. View abstract.
Kim JD, Choi JW, Park HO, et al. Chemical pleurodesis with Viscum album L. extract for secondary spontaneous pneumothorax in elderly patients. J Thorac Dis 2020;12(10):5440-5445. View abstract.
Kim KC, Yook JH, Eisenbraun J, Kim BS, Huber R. Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med. 2012 Oct 3;12:172. View abstract.
Kim M, Park Y, Lee S, and et al. [Comparative study on the effects of a Viscum album (L.) extract (mistletoe) and doxycycline for pleurodesis in patients with malignant pleural effusion]. Korean Journal of Medicine 1999;57(suppl 2):s121.
Kirchberger, I., Wetzel, D., and Finger, T. Development and validation of an instrument to measure the effects of a mistletoe preparation on quality of life of cancer patients: the Life Quality Lectin-53 (LQL-53) Questionnaire. Qual.Life Res. 2004;13(2):463-479. View abstract.
Kleeberg, U. R., Suciu, S., Brocker, E. B., Ruiter, D. J., Chartier, C., Lienard, D., Marsden, J., Schadendorf, D., and Eggermont, A. M. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur.J Cancer 2004;40(3):390-402. View abstract.
Kuttan G, Kuttan R. Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 1992;66:123-30.. View abstract.
Kuttan G, Vasudevan DM, Kuttan R. Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Lett 1988;41:307-14.. View abstract.
Kuttan G, Vasudevan DM, Kuttan R. Presence of a receptor for the active component of Iscador in ascites fluid of tumour bearing mice. Cancer Lett 1989;48:223-7.. View abstract.
Lee YG, Jung I, Koo DH, et al. Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer. Support Care Cancer 2019;27(5):1945-9. View abstract.
Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther 2020;20(1):227. View abstract.
Longhi A, Cesari M, Serra M, Mariani E. Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. Sarcoma 2020;2020:8260730. View abstract.
Longhi A, Reif M, Mariani E, Ferrari S. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med. March 2014:210198. View abstract.
Natl Cancer Inst. Mistletoe (PDQ). CancerNet. www.cancernet.nci.nih.gov/cam/mistletoe.htm#7 (Accessed 30 March 2001).
Nazaruk J, Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res. 2016;30(4):373-85. View abstract.
Noh D, Park JS, Lee DY. Acute respiratory distress syndrome after Viscum album pleurodesis for primary spontaneous pneumothorax. Koren J THorac Cariodvasc Surg. 2017 Feb;50(1):64-67. View abstract.
Olsnes S, Stirpe F, Sandvig K, Pihl A. Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 1982;257:13263-70.. View abstract.
Pelzer F, Tröger W, Nat DR. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. J Altern Complement Med. 2018;24(9-10):954-961. View abstract.
Piao, B. K., Wang, Y. X., Xie, G. R., Mansmann, U., Matthes, H., Beuth, J., and Lin, H. S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 2004;24(1):303-309. View abstract.
Salzer G, Danmayr E, Wutzlhofer F, and et al. [Adjuvant Iscador treatment of operated non small cell lung cancer]. Dtsch Zschr Onkol 1991;23(4):93-98.
Schad F, Atxner J, Buchwald D, Happe A, Popp S, Kröz M, Matthes H. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis. Integr Cancer Ther. 2014 Jul;13(4):332-40. View abstract.
Schad F, Axtner J, Kroz M, Matthes H, Steele ML. Safety of combined treatment with monoclonal antibodies and Viscum album L preparations. Integr Cancer Ther. 2018 Mar;17(1):41-51. View abstract.
Schad F, Thronicke A, Steele ML, et al. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One. 2018;13(8):e0203058. View abstract.
Schaefermeyer G, Schaefermeyer H. Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med 1998;6:172-7.
Schoffski P, Breidenbach I, Krauter J, et al. Weekly 24 h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours. Eur J Cancer 2005;41:1431-8. View abstract.
Semiglasov, V. F., Stepula, V. V., Dudov, A., Lehmacher, W., and Mengs, U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res. 2004;24(2C):1293-1302. View abstract.
Semiglazov, V. F., Stepula, V. V., Dudov, A., Schnitker, J., and Mengs, U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 2006;26(2B):1519-1529. View abstract.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med. 2014;2014:724258. View abstract.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med. 2014;2014:236310. View abstract.
Steele ML, Axtner J, Happe A, Kroz M, Matthes H, Schad F. Use and safety of intratumoral application of European mistletoe (Visum album L) preparations in oncology. Integr Cancer Ther. 2015 Mar;14(2):140-8. View abstract.
Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37:23-31.. View abstract.
Stirpe F, Sandvig K, Olsnes S, et al. Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem 1982;257:13271-7.. View abstract.
Styczynski J, Wysocki M. Alternative medicine remedies might stimulate viability of leukemic cells. Pediatr Blood Cancer 2006;46:94-8. View abstract.
Thronicke A, Matthes B, von Trott P, Schad F, Grah C. Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study. Integr Cancer Ther 2020;19:1534735420940384. View abstract.
Thronicke A, Steele ML, Grah C, Matthes B, Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med. 2017 Dec 13;17(1):534. View abstract.
Timoshenko AV, Cherenkevich SN, Gabius HJ. Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 1995;49:153-8.. View abstract.
Tröger W, Galun D, Reif M, Schumann A, Stankovic N, Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013 Dec;49(18):3788-97. View abstract.
Tusenius KJ, Spoek JM, Kramers CW. Iscador Qu for chronic hepatitis C: an exploratory study. Complement Ther Med 2001;9:12-6.. View abstract.
von Schoen-Angerer T, Wilkens J, Kienle GS, Kiene H, Vagedes J. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series. Perm J. 2015 Fall;19(4):76-83. View abstract.
Weissenstein U, Kunz M, Urech K, Regueiro U, Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med. 2016 Aug 4;16:271. View abstract.
Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series. Complement Ther Med. 2018;40:198-202. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.